Prospective study reports higher efficacy of sonidegib over vismodegib in patients with advanced BCC, indicating improved treatment protocols.
Key Points
Sonidegib shows an overall response rate of 89.5%, surpassing vismodegib's 60.6% in treating advanced BCC.
Among vismodegib-treated patients, 27.5% achieved complete response, while sonidegib had a complete response rate of 36.8%.
This prospective study, conducted over 10 years in Italy, included 66 patients and collected extensive efficacy and safety data.
Findings suggest that changing treatment from vismodegib to sonidegib maintains effectiveness, highlighting potential for future management strategies.